ardiac), abdominal, pelvic cavities, and the retroperitoneal space [see clinical studies (14.2) ].

s (nsf) among patients with impaired elimination of the drugs. avoid use of gbcas among these patients unless the diagnostic information is essential and not available with non-contrast enhanced mri or other modalities. the gbca-associated nsf risk appears highest for patients with chronic, severe kidney disease (gfr < 30 ml/min/1.73m 2 ) as well as patients with acute kidney injury. do not administer omniscan to these patients. the risk appears lower for patients with chronic, moderate kidney disease (gfr 30-59 ml/min/1.73m 2 ) and little, if any, for patients with chronic, mild kidney disease (gfr 60-89 ml/min/1.73m 2 ). nsf may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. report any diagnosis of nsf following omniscan administration to ge healthcare (1-800-654-0118) or fda (1-800-fda-1088 or www.fda.gov/medwatch). screen patients for acute kidney injury and other conditions that may reduce renal function. features of acute kidney injury consist of rapid (over hours to days) and usually reversible decrease in kidney function, commonly in the setting of surgery, severe infection, injury or drug-induced kidney toxicity. serum creatinine levels and estimated gfr may not reliably assess renal function in the setting of acute kidney injury. for patients at risk for chronically reduced renal function (e.g., age > 60 years, diabetes mellitus or chronic hypertension), estimate the gfr through laboratory testing. among the factors that may increase the risk for nsf are repeated or higher than recommended doses of a gbca and the degree of renal impairment at the time of exposure. record the specific gbca and the dose administered to a patient. when administering a gbca, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent prior to any readministration [ see boxed warning , contraindications (4) , clinical pharmacology (12.2) and dosage and administration (2) ]. 5.3 hypersensitivity reactions anaphylactoid and anaphylactic reactions, with cardiovascular, respiratory and/or cutaneous manifestations, resulting in death have occurred. personnel trained in resuscitation techniques and resuscitation equipment should be present prior to omniscan administration. if a hypersensitivity reaction occurs, stop omniscan injection and immediately begin appropriate therapy. observe patients closely, particularly those with a history of drug reactions, asthma, allergy or other hypersensitivity disorders, during and up to several hours after omniscan injection. 5.4 gadolinium retention gadolinium is retained for months or years in several organs. the highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (e.g. brain, skin, kidney, liver, and spleen). the duration of retention also varies by tissue and is longest in bone. linear gbcas cause more retention than macrocyclic gbcas. at equivalent doses, gadolinium retention varies among the linear agents with omniscan (gadodiamide) and optimark (gadoversetamide) causing greater retention than other linear agents [eovist (gadoxetate disodium), magnevist (gadopentetate dimeglumine), multihance (gadobenate dimeglumine)]. retention is lowest and similar among the macrocyclic gbcas [dotarem (gadoterate meglumine), gadavist (gadobutrol), prohance (gadoteridol)]. consequences of gadolinium retention in the brain have not been established. pathologic and clinical consequences of gbca administration and retention in skin and other organs have been established in patients with impaired renal function [ see warnings and precautions (5.2) ] . there are rare reports of pathologic skin changes in patients with normal renal function. adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention [ see adverse reactions (6.3) ] . while clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. these include patients requiring multiple lifetime doses, pregnant and pediatric patients [ see use in specific populations (8.1 , 8.4 ) ], and patients with inflammatory conditions. consider the retention characteristics of the agent when choosing a gbca for these patients. minimize repetitive gbca imaging studies, particularly closely spaced studies when possible. 5.5 acute renal failure in patients with renal insufficiency, acute renal failure requiring dialysis or worsening renal function have occurred, mostly within 48 hours of omniscan injection. the risk of renal failure may increase with increasing dose of gadolinium contrast. use the lowest necessary dose of contrast and evaluate renal function in patients with renal insufficiency. acute renal failure was observed in < 1% of patients in omniscan clinical studies [see adverse reactions (6) ]. omniscan is cleared by glomerular filtration. hemodialysis also enhances omniscan clearance [ see use in specific populations (8.5 , 8.6) ]. 5.6 impaired visualization of lesions detectable with non-contrast mri paramagnetic contrast agents such as omniscan might impair the visualization of lesions which are seen on the non-contrast mri. this may be due to effects of the paramagnetic contrast agent, or imaging parameters. exercise caution when omniscan mri scans are interpreted in the absence of a companion non-contrast mri. 5.7 laboratory test findings asymptomatic, transitory changes in serum iron have been observed. the clinical significance is unknown. omniscan interferes with serum calcium measurements with some colorimetric (complexometric) methods commonly used in hospitals, resulting in serum calcium concentrations lower than the true values. in patients with normal renal function, this effect lasts for 12-24 hours. in patients with decreased renal function, the interference with calcium measurements is expected to last during the prolonged elimination of omniscan. after patients receive omniscan, careful attention should be used in selecting the type of method used to measure calcium.

ommended dose of omniscan is 0.2 ml/kg (0.1 mmol/kg) [see dosage and administration (2.3) ]. 2.3 dosage chart body weight pediatric adults 0.05 0.1 0.05 0.1 kg lb (mmol/kg) (mmol/kg) volume (ml) volume (ml) 12 26 1.2 2.4 - - 14 31 1.4 2.8 - - 16 35 1.6 3.2 - - 18 40 1.8 3.6 - - 20 44 2 4 - - 22 48 2.2 4.4 - - 24 53 2.4 4.8 - - 26 57 2.6 5.2 - - 28 62 2.8 5.6 - - 30 66 3 6 - - 40 88 4 8 4 8 50 110 5 10 5 10 60 132 6 12 6 12 70 154 7 14 7 14 80 176 8 16 8 16 90 198 - - 9 18 100 220 - - 10 20 110 242 - - 11 22 120 264 - - 12 24 130 the heaviest patient in clinical studies weighed 136 kg. 286 - - 13 26 2.4 dosing guidelines inspect omniscan visually for particulate matter and discoloration before administration, whenever solution and container permit. do not use the solution if it is discolored or particulate matter is present. draw omniscan into the syringe and use immediately. discard any unused portion of omniscan injection. to ensure complete delivery of the desired volume of contrast medium, follow the injection of omniscan with a 5 ml flush of 0.9% sodium chloride, as provided in the prefill plus needle-free system. complete the imaging procedure within 1 hour of administration of omniscan. 2.5 directions for proper use of omniscan pharmacy bulk package use only a suitable work area, such as a laminar flow hood, to withdraw omniscan injection doses from the pharmacy bulk package. penetrate the pharmacy bulk package container closure only once using a suitable transfer device and aseptic technique. once the closure is penetrated, withdraw the container contents without delay. if delay is unavoidable, complete the fluid transfer as soon as possible within a maximum time of 8 hours. once the closure is penetrated, keep the pharmacy bulk package container in the aseptic area and at room temperature (do not exceed 30ºc). following withdrawal of any dose from the pharmacy bulk package, immediately label the dose with the supplied peel-off label that identifies the dose contents as omniscan and that omniscan is not for intrathecal use. use each individual dose of omniscan injection immediately following withdrawal from the pharmacy bulk package container; discard any unused portion of the omniscan injection dose not used immediately. discard any unused omniscan doses remaining in the pharmacy bulk package 8 hours after the penetration of the container closure.

. the most frequent adverse reactions were nausea, headache, and dizziness that occurred in 3% or less of the patients. the majority of these reactions were of mild to moderate intensity. the following adverse reactions occurred in 1% or less of patients: application site disorders: injection site reaction. autonomic nervous system disorders: vasodilation. body as a whole-general disorders: anaphylactoid reactions (characterized by cardiovascular, respiratory, and cutaneous symptoms), fever, hot flushes, rigors, fatigue, malaise, pain, syncope. cardiovascular disorders: cardiac failure, rare arrhythmia and myocardial infarction resulting in death in patients with ischemic heart disease, flushing, chest pain, deep thrombophlebitis. central and peripheral nervous system disorders: convulsions including grand mal, ataxia, abnormal coordination, paresthesia, tremor, aggravated multiple sclerosis (characterized by sensory and motor disturbances), aggravated migraine. gastrointestinal system disorders: abdominal pain, diarrhea, eructation, dry mouth/vomiting, melena. hearing and vestibular disorders: tinnitus. liver and biliary system disorders: abnormal hepatic function. musculoskeletal system disorders: arthralgia, myalgia. respiratory system disorders: rhinitis, dyspnea. skin and appendage disorders: pruritus, rash, erythematous rash, sweating increased, urticaria. special senses, other disorders: taste loss, taste perversion. urinary system disorders: acute reversible renal failure. vision disorders: abnormal vision. 6.2 clinical studies experience (pediatrics) in the 97 pediatric patients in cns studies with omniscan [see clinical studies (14.1) ] and the 144 pediatric patients in published literature, the adverse reactions were similar to those reported in adults. 6.3 postmarketing experience because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. the following adverse reactions have been identified during the postmarketing use of omniscan: nervous system disorders: inadvertent intrathecal use causes convulsions, coma, paresthesia, paresis. convulsions have also been reported with intravenous use in patients with and without a history of convulsions or brain lesions. general disorders : nephrogenic systemic fibrosis (nsf) [see warnings and precautions (5.2) ]. adverse events with variable onset and duration have been reported after gbca administration [ see warnings and precautions (5.4) ] . these include fatigue, asthenia, pain syndromes, and heterogeneous clusters of symptoms in the neurological, cutaneous, and musculoskeletal systems . renal and urinary system disorders: in patients with pre-existing renal insufficiency: acute renal failure, renal impairment, blood creatinine increased [see warnings and precautions (5.5) ]. skin : gadolinium associated plaques.

defects and miscarriage in clinically recognized pregnancies is 2 – 4 % and 15 – 20 %, respectively. data human data contrast enhancement is visualized in the human placenta and fetal tissues after maternal gbca administration. cohort studies and case reports on exposure to gbcas during pregnancy have not reported a clear association between gbcas and adverse effects in the exposed neonates. however, a retrospective cohort study, comparing pregnant women who had a gbca mri to pregnant women who did not have an mri, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving gbca mri. limitations of this study include a lack of comparison with non-contrast mri and lack of information about the maternal indication for mri. overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of gbcas in pregnancy. animal data gadolinium retention gbcas administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months. gbcas administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one-month postnatal age. reproductive toxicology gadodiamide has been shown to have an adverse effect on embryo-fetal development in rabbits at dosages as low as 0.5 mmol/kg/day for 13 days during gestation (approximately 0.6 times the human dose based on a body surface area comparison). these adverse effects are observed as an increased incidence of flexed appendages and skeletal malformations which may be due to maternal toxicity since the body weight of the dams was reduced in response to gadodiamide administration during pregnancy. in rat studies, fetal abnormalities were not observed at doses up to 2.5 mmol/kg/day for 10 days during gestation (1.3 times the maximum human dose based on a body surface area comparison); however, maternal toxicity was not achieved in these studies and a definitive conclusion about teratogenicity in rats at doses above 2.5 mmol/kg/day cannot be made. 8.2 lactation risk summary there are no data on the presence of gadodiamide in human milk, the effects on the breastfed infant, or the effects on milk production. however, published lactation data on other gbcas indicate that 0.01 to 0.04% of the maternal gadolinium dose is excreted in breast milk. additionally, there is limited gbca gastrointestinal absorption in the breast-fed infant. animal data show transfer of gadodiamide into rat milk (see data ). the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for omniscan and any potential adverse effects on the breastfed infant from omniscan or from the underlying maternal condition. data gadodiamide is detected in the breast milk of rats injected intravenous with 0.3mmol/kg up to 4 hours post dosing and is below the level of quantification after 8 hours. 8.4 pediatric use the safety and efficacy of omniscan at a single dose of 0.05 to 0.1 mmol/kg have been established in pediatric patients over 2 years of age based on adequate and well controlled studies of omniscan in adults, a pediatric cns imaging study, and safety data in the scientific literature. however, the safety and efficacy of doses greater than 0.1 mmol/kg and of repeated doses have not been studied in pediatric patients. pharmacokinetics of omniscan have not been studied in pediatrics. the glomerular filtration rate of neonates and infants is much lower than that of adults. the pharmacokinetics volume of distribution is also different. therefore, the optimal dosing regimen and imaging times in patients under 2 years of age have not been established. 8.5 geriatric use in clinical studies of omniscan, 243 patients were between 65 and 80 years of age while 15 were over 80. no overall differences in safety or effectiveness were observed between these patients and younger patients. other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity in the elderly cannot be ruled out. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. omniscan is excreted by the kidney, and the risk of toxic reactions to omniscan may be greater in patients with impaired renal function [see warnings and precautions (5.4) ]. because elderly patients are more likely to have decreased renal function, select dose carefully and consider assessment of renal function before omniscan use. 8.6 renal/hepatic impairment dose adjustments in renal or hepatic impairment have not been studied. caution should be exercised in patients with impaired renal insufficiency [ see warnings and precautions (5.2 , 5.5) ].

data contrast enhancement is visualized in the human placenta and fetal tissues after maternal gbca administration. cohort studies and case reports on exposure to gbcas during pregnancy have not reported a clear association between gbcas and adverse effects in the exposed neonates. however, a retrospective cohort study, comparing pregnant women who had a gbca mri to pregnant women who did not have an mri, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving gbca mri. limitations of this study include a lack of comparison with non-contrast mri and lack of information about the maternal indication for mri. overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of gbcas in pregnancy. animal data gadolinium retention gbcas administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months. gbcas administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one-month postnatal age. reproductive toxicology gadodiamide has been shown to have an adverse effect on embryo-fetal development in rabbits at dosages as low as 0.5 mmol/kg/day for 13 days during gestation (approximately 0.6 times the human dose based on a body surface area comparison). these adverse effects are observed as an increased incidence of flexed appendages and skeletal malformations which may be due to maternal toxicity since the body weight of the dams was reduced in response to gadodiamide administration during pregnancy. in rat studies, fetal abnormalities were not observed at doses up to 2.5 mmol/kg/day for 10 days during gestation (1.3 times the maximum human dose based on a body surface area comparison); however, maternal toxicity was not achieved in these studies and a definitive conclusion about teratogenicity in rats at doses above 2.5 mmol/kg/day cannot be made.

al vascularity allows accumulation of omniscan in lesions such as neoplasms, abscesses, and subacute infarcts. the pharmacokinetic parameters of omniscan in various lesions are not known. 12.3 pharmacokinetics the pharmacokinetics of intravenously administered gadodiamide in normal subjects conforms to an open, two-compartment model with mean distribution and elimination half-lives (reported as mean ± sd) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively. gadodiamide is eliminated primarily in the urine with 95.4 ± 5.5% (mean ± sd) of the administered dose eliminated by 24 hours. the renal and plasma clearance rates of gadodiamide are nearly identical (1.7 and 1.8 ml/min/kg, respectively), and are similar to that of substances excreted primarily by glomerular filtration. the volume of distribution of gadodiamide (200 ± 61 ml/kg) is equivalent to that of extracellular water. gadodiamide does not bind to human serum proteins in vitro. following gbca administration, gadolinium is present for months or years in brain, bone, skin, and other organs [ see warnings and precautions (5.4) ]. pharmacokinetic and pharmacodynamic studies have not been systematically conducted to determine the optimal dose and imaging time in patients with abnormal renal function or renal failure, in the elderly, or in pediatric patients with immature renal function.

atically conducted to determine the optimal dose and imaging time in patients with abnormal renal function or renal failure, in the elderly, or in pediatric patients with immature renal function.

/kg followed by 0.2 mmol/kg) has not been established. omniscan as a single 0.1 mmol/kg dose was evaluated in 97 pediatric patients with a mean age of 8.9 (2-18) years referred for cns mri. postcontrast mri provided added diagnostic information, diagnostic confidence, and new patient management information in 76%, 67%, and 52%, respectively, of pediatrics. 14.2 body (intrathoracic [noncardiac], intra-abdominal, pelvic and retroperitoneal regions) omniscan was evaluated in a controlled trial of 276 patients referred for body mri. these patients had a mean age of 57 (9-88) years. patients received 0.1 mmol/kg omniscan for imaging the thorax (noncardiac), abdomen, and pelvic organs, or a dose of 0.05 mmol/kg for imaging the kidney. pre- and post-omniscan images were evaluated blindly for the degree of diagnostic value rated on a scale of "remarkably improved, improved, no change, worse, and cannot be determined." the postcontrast results showed "remarkably improved" or "improved" diagnostic value in 90% of the thorax, liver, and pelvis patients, and in 95% of the kidney patients. in a dose ranging study 258 patients referred for body mri received omniscan 0.025, 0.05, 0.1 mmol/kg. the lowest effective dose of omniscan for the kidney was 0.05 mmol/kg.

muscle weakness. gadolinium retention advise patients that gadolinium is retained for months or years in brain, bone, skin, and other organs in patients with normal renal function. the clinical consequences of retention are unknown. retention depends on multiple factors and is greater following administration of linear gbcas than following administration of macrocyclic gbcas [ see warnings and precautions (5.4) ] .